Turmeric Extract Is Expected To Develop A New Generation Of Anti-cancer Drug Without Chemotherapy Resistance

The common obstacle to the treatment of pancreatic cancer is resistance. However, new studies have shown that curcumin, a compound that can be found in turmeric, can help overcome resistance to chemotherapy.
Curcumin is an active compound found in plants such as turmeric. More and more studies have pointed out the therapeutic potential of the compounds in various conditions such as cancer and diabetes mellitus.
Preclinical studies have shown that the compounds have a variety of antioxidant, neuroprotective, anti-inflammatory and anti-cancer effects.
However, when taken orally, the compound is rapidly metabolized and eliminated from the human body. Thus, more clinical studies and trials are needed to test their possible therapeutic benefits - either alone or in combination with other types of conventional therapy.
The new study helps to fill the gaps in this study because it tests the benefits of curcumin combined with traditional chemotherapy in the treatment of pancreatic cancer.
In particular, the new study investigates the potential of curcumin to overcome chemical resistance, which is a common challenge in the treatment of pancreatic ductal adenocarcinoma (PDAC).
The study was conducted by researchers led by Dr. Ajay Goel, Director of Gastrointestinal Research and Translation Genomics and Oncology at the Baylor Scott and White Institute, Dallas, Texas.
Inhibition of drug resistance
Cancer stem cells are thought to be the main cause of PDAC in the development of chemotherapeutic resistance; studies have shown that they have the ability to have chemotherapy and may be the main cause of metastasis.
However, as explained by the authors of the new study, other studies have shown that curcumin may prevent this acquired chemical resistance, although the exact molecular mechanism of this potential benefit is unknown.
Recent evidence suggests that the so-called subunit of the combinatorial proteome is a key factor in maintaining stem cells. Multi-comb proteins play a key role in stem cell differentiation, and combo complex 2 subunits have shown resistance to drug resistance.
The subunit is called an enhancer of Zeste homolog 2 (EZH2) whose abnormal expression has been shown to block the effect of tumor suppressor.
Dr. Goel and colleagues use curcumin to treat pancreatic cells when inhibiting EZH2 pathway, making cells more receptive to chemotherapy.
In addition, the researchers found that curcumin blocked the formation of spheroids in cell cultures, suggesting that it also inhibited tumor growth and recurrence.
"By treating certain cells with low-dose curcumin, we are able to reverse the pathways that lead to chemical resistance," Dr. Goel said.
"This is an important breakthrough that can lead to better prognosis and longer life for patients with chemotherapy-resistant pancreatic cancer."
Dr. Ajay Goel's previous studies have shown that curcumin has a preventive effect, but the author's knowledge that this is the first to show the beneficial effects of combination of plant extracts and chemotherapy and its advantages in overcoming drug resistance.
Dr. Goel and his team hope that this natural compound has a unique therapeutic potential. He concluded: "Food-based plant drugs are likely to restore more healthy gene expression to patients, but without the toxicity of certain drugs.

For more details please kindly visit: http://www.mwprochem.com